Invivyd (NASDAQ:IVVD) Given New $10.00 Price Target at HC Wainwright

Invivyd (NASDAQ:IVVD - Free Report) had its price objective cut by HC Wainwright from $15.00 to $10.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th.

Invivyd Stock Performance

Shares of Invivyd stock remained flat at $0.77 during trading hours on Wednesday. The stock had a trading volume of 1,033,038 shares, compared to its average volume of 636,176. Invivyd has a 12 month low of $0.72 and a 12 month high of $5.20. The stock has a fifty day moving average of $0.99 and a 200 day moving average of $1.26. The stock has a market cap of $91.88 million, a P/E ratio of -0.40 and a beta of 0.65.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock valued at $11,594,000 after buying an additional 97,496 shares during the last quarter. State Street Corp grew its holdings in Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company's stock valued at $1,039,000 after purchasing an additional 35,904 shares during the period. Marshall Wace LLP boosted its holdings in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after buying an additional 31,992 shares during the period. Acadian Asset Management LLC lifted its position in Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock worth $745,000 after buying an additional 474,301 shares in the last quarter. Finally, Duquesne Family Office LLC acquired a new position in Invivyd during the second quarter worth $629,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.